Jacobs Journal of Epidemiology and Preventive Medicine
Low Percentage of Asylum Seekers Colonized with Multi-Resistant Bacteria Treated at a German Hospital
*Stefan Borgmann Department Of Infectious Diseases And Infection Control, Germany, Germany
*Corresponding Author: Stefan Borgmann
Department Of Infectious Diseases And Infection Control, Germany, Germany Email:firstname.lastname@example.org
Published on: 2018-01-30
To assess whether asylum seekers show increased colonization risk for methicillin resistant Staphylococcus aureus (MRSA)and multi-resistant Gram negative bacteria, approximately 100 patients treated at the hospital in Ingolstadt betweenFebruary and August 2015 were examined for colonization frequency. Four patients (4.2%) were MRSA positive. Eightpatients (8.1%) were colonized by E. coli exhibiting extended spectrum beta-lactamase activity, a percentage similar to thatof German ambulatory patients. In summary, the percentage of asylum seekers colonized with multi-resistant bacteria waslow eliminating the necessity of general screening measures at hospital admission.
Asylum Seekers, Escherichia coli with Expended Spectrum Beta-Lactamase Activity (ESBL), Methicillin-Resistant Staphylococcus aureus (MRSA) in Humans
The Robert-Koch-Institute (RKI) is a department of the German ministry of health (RKI). The Commission of Hospital Hygiene and Infection Prevention (KRINKO) of the RKI recommends the screening of patients with increased colonization probability for methicillin resistant Staphylococcus aureus (MRSA) or multi-resistant Gram negative bacteria (MRGN), e.g. Gram negative bacteria exhibiting extended spectrum beta-lactamase activity (ESBL) during hospital stays at German hospitals. The KRINKO defines Gram negative bacteria as 4-MRGN or 3-MRGN when showing resistance to four or three of the following antibiotic groups, respectively: Acylureidopenicillins (indicator antibiotic: piperacillin), cephalosporines of the 3rd generation (ceftriaxone/cefotaxime), carbapenems (meropenem), and quinolones (ciprofloxacin) .